[go: up one dir, main page]

PE20011022A1 - Compuestos trans olefinicos activadores glucoquinasa - Google Patents

Compuestos trans olefinicos activadores glucoquinasa

Info

Publication number
PE20011022A1
PE20011022A1 PE2000001324A PE0013242000A PE20011022A1 PE 20011022 A1 PE20011022 A1 PE 20011022A1 PE 2000001324 A PE2000001324 A PE 2000001324A PE 0013242000 A PE0013242000 A PE 0013242000A PE 20011022 A1 PE20011022 A1 PE 20011022A1
Authority
PE
Peru
Prior art keywords
phenyl
olefinic compounds
trans
glucokinase activators
propionamide
Prior art date
Application number
PE2000001324A
Other languages
English (en)
Inventor
Wendy Lea Corbett
Ramakanth Sarabu
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20011022A1 publication Critical patent/PE20011022A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UREIDO PROPIONAMIDA O PROPIONAMIDA N-HETEROAROMATICA TRANS OLEFINICA 2,3-DI-SUSTITUIDAS EN LA POSICION 2 POR FENILO, POSICION 3 POR CICLOALQUILO; DE FORMULA I, DONDE R1 Y R2 SON H, HALO, AMINO, NITRO, PERFLUOROALQUILO, ALQUILO, ENTRE OTROS; R ES (CH2)mR3, ALQUILO C2-C4; R3 ES CICLOALQUILO C3-C8, C(=O)NHR7; R4 ES UN ANILLO HETEROAROMATICO DE 5-6 MIEMBROS; m ES 0-1; REPRESENTA CONFIGURACION TRANS; SON COMPUESTOS PREFERIDOS (E)-1-[3-CICLOHEXIL-2-(4-METANOSULFONIL-3-TRIFLUORO-METIL-FENIL)ACRILOIL]-3-METIL-UREA; (E)-3-CICLOPENTIL-2-(4-METANOSULFONIL-FENIL)-N-TIAZOL-2-IL-ACRILAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES ACTIVADOR DE GLUCOQUINASA, AUMENTANDO LA SECRECION DE INSULINA POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE DIABETES II
PE2000001324A 1999-12-15 2000-12-12 Compuestos trans olefinicos activadores glucoquinasa PE20011022A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17078399P 1999-12-15 1999-12-15

Publications (1)

Publication Number Publication Date
PE20011022A1 true PE20011022A1 (es) 2001-10-11

Family

ID=22621235

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001324A PE20011022A1 (es) 1999-12-15 2000-12-12 Compuestos trans olefinicos activadores glucoquinasa

Country Status (33)

Country Link
US (1) US6353111B1 (es)
EP (1) EP1242397B1 (es)
JP (1) JP3824936B2 (es)
KR (1) KR100502032B1 (es)
CN (1) CN1185219C (es)
AR (1) AR032752A1 (es)
AT (1) ATE305461T1 (es)
AU (1) AU781029B2 (es)
CA (1) CA2392903C (es)
CO (1) CO5050295A1 (es)
CZ (1) CZ20022412A3 (es)
DE (1) DE60022903T2 (es)
DK (1) DK1242397T3 (es)
ES (1) ES2249322T3 (es)
GC (1) GC0000264A (es)
HK (1) HK1054383B (es)
HR (1) HRP20020514A2 (es)
HU (1) HUP0203753A3 (es)
IL (2) IL150083A0 (es)
JO (1) JO2180B1 (es)
MA (1) MA26855A1 (es)
MX (1) MXPA02005874A (es)
MY (1) MY125484A (es)
NO (1) NO323142B1 (es)
NZ (1) NZ518974A (es)
PE (1) PE20011022A1 (es)
PL (1) PL355815A1 (es)
RU (1) RU2245332C2 (es)
TW (1) TWI262916B (es)
UY (1) UY26483A1 (es)
WO (1) WO2001044216A1 (es)
YU (1) YU41402A (es)
ZA (1) ZA200203829B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2003080585A1 (en) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
NZ539013A (en) * 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
RU2386622C9 (ru) 2004-01-06 2021-04-21 Ново Нордиск А/С Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
EP1718624B1 (en) 2004-02-18 2009-03-25 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents
CA2561157A1 (en) * 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
RU2412192C2 (ru) * 2004-04-02 2011-02-20 Новартис Аг Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2
CN100567276C (zh) * 2004-04-21 2009-12-09 普罗西迪恩有限公司 三（环）取代的酰胺类化合物
US20080242869A1 (en) * 2004-04-21 2008-10-02 Matthew Fyfe Tri(Cyclo) Substituted Amide Compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US20080026987A1 (en) * 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
WO2006016194A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
JP4651714B2 (ja) 2005-07-09 2011-03-16 アストラゼネカ アクチボラグ 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
EP1951658B1 (en) 2005-11-17 2012-09-26 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
CN107007581A (zh) 2006-08-24 2017-08-04 田纳西大学研究基金会 取代的n‑酰基苯胺及其使用方法
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
US7902248B2 (en) * 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
JP5491871B2 (ja) 2007-02-28 2014-05-14 アドビナス セラピュティックス プライベート リミテッド グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用
EP2116533B1 (en) * 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
WO2009039944A1 (de) * 2007-09-21 2009-04-02 Sanofi-Aventis Phenothiazin derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
RU2010134411A (ru) 2008-01-18 2012-02-27 Астеллас Фарма Инк. (Jp) Фенилацетамидное производное
NZ588462A (en) 2008-04-28 2012-07-27 Kyorin Seiyaku Kk Cyclopentylacrylic acid amide derivative
PE20141375A1 (es) 2008-05-16 2014-10-23 Takeda San Diego Inc Activadores de glucoquinasa
WO2010150280A1 (en) 2009-06-22 2010-12-29 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (gk) activators
JP2013500961A (ja) 2009-07-31 2013-01-10 カディラ ヘルスケア リミテッド グルコキナーゼ（ｇｋ）アクチベーターとしての置換ベンズアミド誘導体
KR100970871B1 (ko) * 2009-11-30 2010-07-20 케이제이알디 (주) 바닥재 어셈블리 및 바닥재의 시공방법
NZ600367A (en) 2009-12-04 2013-08-30 Taisho Pharmaceutical Co Ltd 2-pyridone compounds
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9695148B2 (en) 2012-11-13 2017-07-04 Nissan Chemical Industries, Ltd. 2-pyridone compound
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
AU2021289309A1 (en) 2020-06-08 2023-01-19 Vtv Therapeutics Llc Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5169951A (en) 1990-04-23 1992-12-08 Ciba-Geigy Corporation Process for preparing nematicidal compositions
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
TR200102805T2 (tr) * 1999-03-29 2002-04-22 F.Hoffmann-La Roche Ag Glikokinaz aktivatörleri

Also Published As

Publication number Publication date
RU2245332C2 (ru) 2005-01-27
MY125484A (en) 2006-08-30
DK1242397T3 (da) 2006-02-13
MA26855A1 (fr) 2004-12-20
KR20020067555A (ko) 2002-08-22
YU41402A (sh) 2005-07-19
HUP0203753A3 (en) 2004-12-28
ES2249322T3 (es) 2006-04-01
IL150083A0 (en) 2002-12-01
JP2003516980A (ja) 2003-05-20
KR100502032B1 (ko) 2005-07-25
HUP0203753A2 (hu) 2003-03-28
CA2392903C (en) 2008-08-05
HK1054383B (zh) 2005-04-22
DE60022903T2 (de) 2006-07-06
NO20022863L (no) 2002-06-14
MXPA02005874A (es) 2002-10-23
PL355815A1 (en) 2004-05-17
HRP20020514A2 (en) 2004-06-30
IL150083A (en) 2010-04-15
AU2365201A (en) 2001-06-25
AU781029B2 (en) 2005-04-28
WO2001044216A1 (en) 2001-06-21
TWI262916B (en) 2006-10-01
EP1242397A1 (en) 2002-09-25
CZ20022412A3 (cs) 2002-10-16
US6353111B1 (en) 2002-03-05
ATE305461T1 (de) 2005-10-15
EP1242397B1 (en) 2005-09-28
CA2392903A1 (en) 2001-06-21
JO2180B1 (en) 2003-04-23
GC0000264A (en) 2006-11-01
CN1411453A (zh) 2003-04-16
NO20022863D0 (no) 2002-06-14
DE60022903D1 (de) 2006-02-09
NZ518974A (en) 2004-04-30
AR032752A1 (es) 2003-11-26
JP3824936B2 (ja) 2006-09-20
ZA200203829B (en) 2003-08-14
CN1185219C (zh) 2005-01-19
NO323142B1 (no) 2007-01-08
CO5050295A1 (es) 2001-06-27
HK1054383A1 (en) 2003-11-28
UY26483A1 (es) 2001-06-29

Similar Documents

Publication Publication Date Title
PE20011022A1 (es) Compuestos trans olefinicos activadores glucoquinasa
PE20020335A1 (es) Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa
BR0213243A (pt) Composto, e, ativador de receptor delta ativado por proliferador de peroxissoma
FI940105A0 (fi) Menetelmä sertraliinivälituotteiden valmistamiseksi
DK1302468T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease
PT96096A (pt) Processo de estabilizacao de uma mistura aquosa de um composto heterociclico de azoto e de preparacao de composicoes estabilizadas com metionina
PE20011310A1 (es) Alquinil fenil amidas heteroaromaticas como activadores de la glucokinasa
KR940014337A (ko) 에이즈의 치료에 유용한 에이치아이브이(hiv) 프로테아제 억제제
HUP0004436A2 (hu) FP agonistákként alkalmazható aromás C16-C20-szubsztituált tetrahidroprosztaglandinok
ATE111445T1 (de) Orthosubstituierte biphenylguanidinderivate sowie diese enthaltende antidiabetische oder hypoglykämische mittel.
ATE90074T1 (de) Orthosubstituierte phenylamidine oder phenylguanidine, sowie diese enthaltende antidiabetische oder hypoglykaemische mittel.
FI940106A0 (fi) Menetelmä sertraliinin valmistamiseksi
MY101880A (en) Benzoylphenylureas, the preparation thereof and the use thereof in pest control.
ES2133153T3 (es) Nuevos depsipeptidos ciclicos con 18 atomos de anillo, y su empleo para el combate de endoparasitos.
DK74189D0 (da) Laegemiddel til behandling af mavesaar
PT1050534E (pt) Novos derivados de 2,3-metano-aminoacidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
BR8900238A (pt) Composto de oxadiazol,processo para sua preparacao,composicao pesticida e processo para combater pragas
GB1450801A (en) Pyridinecarboxamide sulphonylurea hypoglycemic agents
DK0398427T3 (da) Antirhinovirale pyridazinaminer
SE8504346L (sv) N-alkyl(en)-n-(o,o-disubstituerad tiofosforyl)-n',n'-disubstituerade glycinamider, sett att framstella dessa samt akaricid, insekticid och fungicid, innehallande dess foreningar som verksam bestandsdel
KR870007108A (ko) 벤조일우레아 화합물의 제조방법
SE8204670D0 (sv) Ny forening med antiulcerogen aktivitet, forfarande for dess framstellning och farmaceutisk beredning innehallande densamma
SE8404906L (sv) Fluoralkylerade karbapenemderivat
ES2143159T3 (es) Nuevos derivados de 2-ciano-3-hidroxi-propenamidas que comprenden un radical trifluorometilsulfonilfenilo/trifluorometilsulfinilfenilo, procedimiento de preparacion, aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
DE3863682D1 (de) N-benzoyl-n'-trihalogen-halogenalkoxy-phenylharnstoffe, ihre herstellung und verwendung bei der kontrolle von schaedlingen.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed